Aim
Introduction
Stroke is associated with major disabilities and mortality. 1 Although over the last decades several novel experimental neuroprotective strategies have been developed, 2 their translation into clinical practice has proven difficult. 3, 4 Thus, the search for novel therapeutic targets for ischaemic stroke as an adjunct to thrombolysis remains an unmet clinical need. Although ischaemic stroke is amenable to thrombolysis in patients presenting early after symptom onset, 5 vascular leakage and the ensuing oedema formation during reperfusion contributes importantly to neurological deficits. 6 Cerebral microvascular endothelial cells are a main component of the blood-brain barrier (BBB) 7 which divides the cerebral circulation from brain tissue. These cells are interconnected by tight and adherens junction proteins 7 whose integrity is critical for stroke outcome. 8 Indeed, disruption of the BBB following ischaemia/reperfusion (I/R) leads to vascular leakage and infiltration of plasma components into the brain tissue leading to oedema and further organ damage. 9 -11 Overproduction of reactive oxygen species (ROS) following I/R is considered a key mechanism leading to BBB damage. 12 p66
Shc , an isoform of the mammalian adaptor protein Shc, 13, 14 is a crucial mediator of ROS production in several disease states 15 -18 thereby leading to cellular apoptosis. 19 -21 Indeed, much of the vasculoprotective properties observed by genetic deletion of p66 Shc in mice are the result of reduced oxidative stress and in turn preserved endothelial function. 15 -17 In line with the above, we previously demonstrated that mice lacking p66
Shc develop smaller stroke size following I/R. 22 However, the clinical relevance of this observation remains unknown and the underlying molecular mechanisms poorly understood. To this end, we subjected mice to I/R brain injury and, to mimic real life clinical conditions as it would occur in the context of thrombolysis, we performed p66 Shc silencing in vivo using small interfering RNA (siRNA) after the ischaemic episode and upon reperfusion. Additionally, we mimicked I/R conditions in primary human brain microvascular endothelial cells (HBMECs) by exposing them to hypoxia/reoxygenation (H/R) with and without silencing of p66 Shc and assessed the production of ROS as well as the levels of tight and adherens junction proteins. Finally, we studied p66 Shc gene expression in peripheral blood monocytes (PBMs) of patients with acute ischaemic stroke and correlated it to the National Institutes of Health Stroke Scale (NIHSS).
Methods Patients
Twenty-seven patients admitted to the emergency room of San Raffaele Hospital (OSR, Milan, Italy) with a diagnosis of acute ischaemic stroke presenting within 6 h from symptom onset were enrolled. Five patients presented wake-up stroke and were recruited within 6 h from awakening. The initial diagnosis was based on clinical history, neurological examination (conducted by certified neurologists), and a brain computed tomography (CT) scan. Nineteen sex-and age-matched healthy volunteers (either relatives or visitors of in-hospital patients), with a negative history of cardio-and cerebrovascular diseases, were included as controls. Patients diagnosed with diabetes, systemic inflammatory diseases, acute infections, and malignancy were excluded, to eliminate potential interference of those disease states on p66 Shc expression. 23 Blood was withdrawn from the antecubital vein at 6 and 24 h after initial stroke symptoms (for stroke patients), whereas control subjects donated blood once. Of the 27 ischaemic stroke patients, 14 received thrombolytic treatment within 4.5 h from initial stroke symptoms onset. Ischaemic strokes were clinically classified according to the Oxford Community Stroke Project classification (also known as the Bamford or OXFORD classification). 24 Stroke aetiology was classified according to the Trial of ORG 10172 in Acute Stroke Treatment criteria. 25 Moreover, stroke severity was assessed, using NIHSS on admission and at discharge. Furthermore, delta NIHSS was calculated as the difference between the NIHSS presented at discharge and the NIHSS presented at admission (delta NIHSS ¼ NIHSS discharge 2 NIHSS admission); thereby, positive values indicate short-term neurologic worsening while negative values indicate neurological improvement. The study was approved by the local Ethics Committee at San Raffaele Scientific Institute, Milan, Italy. All participants (or their representative relatives) signed a written informed consent to authorize the treatment of their biological and clinical data.
Isolation of peripheral blood monocytes
Peripheral blood monocytes from whole blood were isolated using anti-CD14-coated MicroBeads (Miltenyi Biotec) on a magnetic separator (Miltenyi Biotec), as previously described. 26 
Animals
All animal experiments were performed on male, 11 -13-week-old wildtype (wt) (C57/BL6J) mice. Study design and experimental protocols were approved by the Cantonal Veterinary Office of the Canton of Zurich.
Middle cerebral artery occlusion
A transient middle cerebral artery (MCA) occlusion (MCAO) surgery was performed on wt mice to induce I/R brain injury, as described. 22 In brief, anaesthesia was induced with 3% isoflurane in oxygen-enriched air and mice were kept under 1.5% isoflurane anaesthesia during MCAO surgery. Body temperature was controlled by using a warm water heating pad. Incision site was infiltrated with 0.5% bupivacaine solution for pain relief. A 6-0 silicone-coated filament (Doccol Corporation) was advanced into the internal carotid artery (ICA) until the thread occluded the origin of the left MCA to induce unilateral MCAO. After 45 min (60 min for evaluation of long-term effect) of ischaemia, the thread was removed to allow reperfusion of the MCA. After wound care and before returning to their standard cage, mice were kept for 1.5 h in a temperature controlled cage. For sham operation, the filament was advanced into the ICA without occluding the MCA.
In vivo p66 Shc silencing
In vivo p66 Shc silencing was performed as described. 27 Briefly, 1.6 nmol of predesigned siRNA targeting p66 Shc was incubated with a mixture of 150 mmol/L NaCl solution-jetPEI w and injected intravenously into the tail vein of the wt mouse randomized. Scrambled siRNA was used as a negative control. Detailed methods are provided in Supplementary material online.
Magnetic resonance imaging
Lesion development was monitored after MCAO on a Bruker PharmaScan 47/16 (Bruker BioSpin GmbH) operating at 4.7 T. Anaesthesia was induced using 3% isoflurane (Abbott) in a 4 : 1 air-oxygen mixture. During MRI acquisition, mice were kept under isoflurane anaesthesia (1.5%). During the scan session, body temperature was monitored with a rectal temperature probe (MLT415, ADInstruments) and kept at 36 + 0.558C using a warm water circuit integrated into the animal support (Bruker BioSpin GmbH). Magnetic resonance imaging (MRI) recordings were done in a blinded way by an independent person.
The lesion was determined on maps of the apparent diffusion coefficient (ADC) derived from diffusion-weighted images as areas of significant reduction of the ADC compared with the unaffected, contralateral side. The lesion in the T2-weighted image was determined as hyperintense areas compared with the contralateral hemisphere. Lesion volumes were quantified blinded by drawing regions of interest around the areas of reduced ADC and hyperintensities in T2-weighted images in five MRI slices using an ROI tool (Paravision, Bruker). Brain infarct volumes were calculated by summing the volumes of each section and correcting for brain swelling, as described. 28 Detailed methods are provided in Supplementary material online.
Neurological deficits measurement
Neurological status was assessed using an adapted four-point scale test based on Bederson et al. 29 and was graded as previously described 22 :
Grade 0: normal neurological function; Grade 1: forelimb flexion; Grade 2: circling; Grade 3: leaning to the contralateral side at rest; Grade 4: no spontaneous motor activity. Motor performance was assessed using the RotaRod test. Mice were placed on a rotating rod with increasing speed (4 -44 revolutions/min; circumference of the rod: 9 cm) and the latency to fall was measured. The experimental trail was ended if the maximum rotation speed was achieved or if the mouse fell off the rod. Per time point, three test runs per mouse were performed and the best run was included in the statistics. Neurological deficit measurements were performed in a blinded way.
Evaluation of long-term effect
Long-term effect of post-ischaemic in vivo p66 Shc silencing on stroke was assessed up to 6 days. The well-being of mice during the experimental period was determined using a score sheet that was approved by the Cantonal Veterinary Office of the Canton of Zurich. This score sheet was used to define survival/death of an animal. Death events include spontaneous deaths (4 of 16 for siScr stroke mice and 3 of 15 for sip66 Shc stroke mice) and mice which did not fulfil the health evaluation criteria.
Evans blue extravasation
Determination of BBB permeability after MCAO was done by evaluating Evans blue extravasation, as described. 30 Detailed methods are provided in Supplementary material online.
Immunofluorescence staining
Frozen brains were cut into 6 mm thick slices on a cryostat (Leica Cm 1900). Immunofluorescent analysis was performed as described. 31 Briefly, brain slices were fixed in 4% paraformaldehyde and incubated with primary and secondary antibodies. Images were taken using a Leica Dm4000 B microscope. Stained area of claudin-5, vascular endothelial (VE)-cadherin, or occludin was measured using ImageJ Software and normalized to the total endothelial cell surface (assessed by isolectin B 4 staining). Detailed methods are provided in Supplementary material online.
RNA isolation and reverse transcription
Total RNA isolation and preparation of cDNA was performed as previously described. 26 Total RNA of PBM, or of MCA, was extracted using TRIzol Reagent (Invitrogen). Two micrograms (MCA) or 1 mg (PBM) of RNA was reverse transcribed using Ready-To-Go You-Prime FirstStrand Beads (Amersham Biosciences) and first-strand random cDNA primers pd(N)6 (TaKaRa).
Real-time polymerase chain reaction
Determination of p66 Shc gene expression was done as previously described. 26 Detailed methods are provided in Supplementary material online.
Cell culture experiments
Primary HBMECs (Cell Systems) were cultured in EBM-2 medium supplied with EGM-2 bullet kit (Lonza). Adhering cells (passages 5 -9) were grown to confluence and exposed to hypoxia (0.2% oxygen) for 4 h, followed or not by 4 h of incubation in a normoxic incubator (reoxygenation). Hypoxia was induced using a gas-controlled glove box (Invivo2 400, Ruskinn Technologies). In certain experiments, cells were pre-incubated with apocynin (0.1 mmol/L) (SAFC) for 1 h. Thereafter, HBMECs were harvested for measuring superoxide anion (O Immunoblotting Basilar arteries and cells were lysed in lysis buffer and proteins were separated using SDS -PAGE, as previously described. 32 Detailed methods are provided in Supplementary material online.
Measurement of O 2 2 production and nitric oxide bioavailability
Electron spin resonance spectroscopy was applied to determine O − 2 production and NO bioavailability, as described. 27,32 -34 Detailed methods are provided in Supplementary material online.
Nicotinamide adenine dinucleotide phosphate oxidase activity
Nicotinamide adenine dinucleotide phosphate oxidase activity was determined indirectly by measuring the ratio of NADP/NADPH using a commercially available kit (Abcam), according to the manufacturer's recommendations. showed a positive signal for Alexa546-tagged p66 Shc siRNA ( Figure 1F ) while only 0.6% of leukocytes (CD45 + CD31
2 ) ( Figure 1G ) and 0.2% of other nucleated cells (CD45 
CD31
2 ) ( Figure 1H) were positive for the Alexa546 signal. Negative control was stained with Hoechst 33342 to label nucleated cells ( Figure 1L-N) .
Lesion volumes in sip66 Shc and siScr injected stroke mice were quantified with MRI. Diffusion-weighted imaging (DWI) denoted matching baseline lesion sizes in both groups after 45 min of ischaemia and directly upon reperfusion ( Figure 2B ). At 48 h post-MCAO, both DWI and T2-weighted imaging displayed instead a reduced stroke volume in sip66 Shc stroke mice when compared with siScr stroke mice ( Figure 2B and C). Neurological deficits after MCAO were assessed using two different tests. Pre-MCAO, both sip66
Shc and siScr stroke mice showed comparable performance in the RotaRod test and on the four-point scale test based on Bederson et al. 29 ( Figure 2D and E). At 24 h post-MCAO, we observed in both groups a reduced latency to fall in the RotaRod test. However, at 48 h post-MCAO, sip66 Shc stroke mice showed a significant higher persistence on the rotating drum compared with siScr stroke mice ( Figure 2D ). In line with that, neurological deficits assessed with the scale test were significantly lower in sip66 Shc stroke mice compared with siScr stroke mice at 48 h post-MCAO ( Figure 2E ). All sham operated animas displayed normal neurological functions throughout the experimental period ( Figure 2D and data not shown) . By analysing the impact of p66 Shc silencing on stroke up to 6 days, we found an improved survival of sip66 Shc stroke mice when compared with siScr stroke mice ( Figure 2F , 31.25% survival for siScr stroke mice vs. 66.66% for sip66 Shc stroke mice). Survival was assessed in accordance to the health evaluation criteria approved by the Cantonal Veterinary Office of the Canton of Zurich; all sham operated animals survived and fulfilled the health evaluation criteria (data not shown).
In vivo p66 Shc silencing preserves blood -brain barrier integrity after I/R brain injury
The BBB plays a critical role for the outcome of stroke, 8 and its permeability can be assessed in vivo by quantifying Evans blue extravasation. 9, 30 We tested whether post-ischaemic p66
Shc silencing preserves BBB permeability after I/R brain injury in mice. Indeed, 48 h post-MCAO p66 Shc silencing reduced Evans blue extravasation when compared with mice receiving siScr ( Figure 3A ). Blood-brain barrier permeability is regulated by tight and adherens junctional proteins connecting cerebral microvascular endothelial cells. 35 Thus, we analysed the integrity of tight and adherens junctions following I/R brain injury focusing on claudin-5, occludin, and VE-cadherin. Immunofluorescence staining of claudin-5 on coronal brain sections of siScr-treated stroke mice revealed decreased claudin-5-positive stained areas normalized to the total endothelial surface (measured by isolectin B 4 staining 31, 36 ) in the ipsilateral hemisphere compared with the contralateral hemisphere ( Figure 3B ), while this disruption of claudin-5 integrity was not observed in stroke mice receiving sip66 Shc ( Figure 3B ). Unlike claudin-5, occludin and VE-cadherin-positive stained areas were not changed following I/R brain injury in both experimental groups (data not shown).
Role of p66 Shc in H/R in primary human brain microvascular endothelial cells
In order to characterize the molecular regulation of claudin-5 by p66
Shc and to translate our in vivo murine data to human cells, we exposed HBMECs to hypoxia (H) alone, or hypoxia followed by reoxygenation (H/R). Exposure of HBMECs to hypoxia neither altered phosphorylation of p66 Shc at Ser36, a critical step for its pro-apoptotic 37 and pro-oxidant activity, 21 nor total p66 Shc protein Post-ischaemic silencing of p66 Shc reduces ischaemia/reperfusion brain injury levels significantly, compared with normoxia ( Figure 4A ). In contrast, exposure to H/R increased phosphorylation of p66 Shc at Ser36 compared with normoxia ( Figure 4B ). Hypoxia-inducible factor-1a protein stabilization was used as an indicator of effective hypoxic conditions ( Figure 4A ). Reactive oxygen species and NO are critical for endothelial function 20 and have been implicated in vascular permeability. 12 Here, we analysed whether H/R regulates O − 2 production and NO bioavailability, and whether p66
Shc mediates these effects.
Exposure of HBMECs to H/R led to an increased O − 2 production ( Figure 4D ) and a decreased NO bioavailability ( Figure 4E ) compared with normoxia. However, endothelial NO synthase (eNOS) phosphorylation at both sites studied (Ser1177 and Thr495) and eNOS protein expression remained unchanged ( Figure 4F and G) . Preincubation of HBMECs with p66
Shc siRNA, but not scrambled siRNA, reduced the increased O − 2 production ( Figure 4D ) and increased the reduced NO bioavailability during H/R ( Figure 4E) . Indeed, NADPH oxidase activity was increased after exposure to H/R, and returned to control levels after silencing of p66 Shc ( Figure 4H ).
Effect of p66
Shc and reactive oxygen species on claudin-5 in vitro Human brain microvascular endothelial cells exposed to H/R exhibited reduced protein levels of claudin-5 compared with normoxia ( Figure 5A ). In contrast, occludin and VE-cadherin protein levels were not affected by exposure to H/R ( Figure 5B and C) . After both, pre-incubation of HBMECs with p66
Shc siRNA and with the antioxidant apocynin 41 claudin-5 levels were elevated under H/R condition ( Figure 5D and E). p66 Shc gene expression is increased in patients with ischaemic stroke and correlates to neurological outcome
To provide evidence for a role of p66 Shc in human ischaemic stroke, we analysed p66 Shc expression in PBMs of patients with ischaemic stroke. A total of 27 ischaemic stroke patients and 19 age-and sexmatched, healthy control subjects were recruited. Clinical characteristics of both groups did not differ statistically ( Table 1) . p66 Shc mRNA levels were significantly increased 6 h after initial stroke symptoms ( Figure 6A ) and returned to control levels 24 h thereafter ( Figure 6A ). Of note, p66
Shc gene expression at 6 h was comparable in patients with ischaemic stroke regardless of whether they had received thrombolytic treatment or not ( Figure 6B ). p66 Shc transcript levels of all study subjects positively correlated with neurological deficits at admission, measured according to the NIHSS ( Figure 6C ). Importantly, while p66 Shc gene expression of stroke patients which did not receive thrombolytic intervention did not correlate with shortterm neurological outcome (NIHSS discharge 2 NIHSS admission) ( Figure 6D ), it positively correlated in stroke patients treated with thrombolysis ( Figure 6E ).
Discussion
In this study, we demonstrate for the first time that post-ischaemic p66 Shc silencing reduces brain injury by preserving BBB integrity by preventing claudin-5 level downregulation. The in vivo findings in the mouse were translated to HBMECs exposed to H/R where p66 Shc was phosphorylated at Ser36 leading to the reduction in claudin-5 levels via activation of the NADPH oxidase and increased ROS production. Further, we show that p66 Shc expression is increased in PBMs of patients with ischaemic stroke within 6 h from onset of symptoms and that p66 Shc gene expression correlates to short-term neurological outcome. In mice, we recently showed that constitutive genetic deletion of p66
Shc reduces early stroke size and neurological deficits following I/R brain injury. 22 However, the mechanisms of this effect and its clinical relevance remained elusive. Furthermore, the use of constitutive knockout animals only serves as a proof-of-principle and does not allow delineation of therapeutic time windows as required in the clinical setting. In contrast, RNA interference (RNAi)-based strategies allow to modify the expression of a certain target at the posttranscriptional level, thus making it therapeutically interesting. 42 Indeed, several RNAi-based strategies are under investigation in clinical trials. 43 Here, we used a clinically relevant experimental setup with siRNA delivery upon reperfusion to reduce p66 Shc levels.
Reperfusion of an occluded vessel allows reoxygenation of the ischaemic area which promotes recovery of penumbral areas. 44 Nevertheless paradoxically, re-introduction of oxygen in a previously ischaemic area also causes a surge in free radical generation 11 which interferes with the recovery processes. Indeed, we demonstrate here that silencing of the pro-oxidant p66 Shc after the ischaemic episode and upon reperfusion, as it would be the case in stroke patients presenting at the emergency room undergoing thrombolytic treatment, reduces lesion volume, improves neurological function, and increases survival. These data highlight the potential of p66 Shc as novel therapeutic target in stroke patients undergoing thrombolysis. Given the key role of BBB permeability in determining stroke outcome, 6 we characterized its integrity by analysing Evans blue extravasation, a known indicator for vascular leakage. 9, 30, 31, 45 Indeed, and in line with the improved stroke outcome in the sip66 Shc stroke mice, BBB disruption was blunted after p66 Shc silencing compared with control mice. Cerebral microvascular endothelial cells connected via tight and adherens junctional proteins make up the BBB. 7 A disruption of this tightly regulated structure is known to occur in I/R brain injury and is responsible for vascular leakage and in turn oedema formation. 9 -11 To investigate the molecular mechanisms by which p66 Shc preserves BBB integrity after I/R brain injury, we focused in vivo as well as in vitro on claudin-5, occludin and VE-cadherin, three major junctional proteins. Clinical characteristics of controls and stroke patients do not differ statistically. Sub-group analysis shows statistically significant differences in age and NIHSS at discharge between patients treated with thrombolysis and patients which did not receive thrombolysis. Age is given as mean (with ranges) and NIHSS is expressed as mean + SD. TIA, transient ischaemic attack; tPA, tissue plasminogen activator; TACI, total anterior circulation infarct; PACI, partial anterior circulation infarct; LACI, lacunar infarct; POCI, posterior circulation infarct; TOAST, Trial of ORG 10172 in Acute Stroke Treatment; NIHSS, National Institutes of Health Stroke Scale. a Haemorrhagic transformation and cerebral oedema were determined in stroke patients (n ¼ 23; tPA n ¼ 13, w/otPA n ¼ 10) on CT scan at 24 h after initial stroke symptoms.
found less reduction in claudin-5 levels after silencing of p66 Shc . In contrast, occludin and VE-cadherin levels remained unaltered in both experimental settings. Our data obtained on murine as well as primary human cells indicate that p66 Shc mediates BBB disruption by acting specifically on claudin-5 rather than occludin and VE-cadherin.
To characterize the molecular regulation of claudin-5 by p66
Shc , we exposed primary HBMECs to H/R, to mimic in vivo settings. Exposure of HBMECs to H/R, but not to hypoxia, increased phosphorylation of p66
Shc at Ser36 confirming previous data in renal tubular epithelial cells. 46 Together with our in vivo data, these results suggest that p66 Shc is mainly involved in mediating its deleterious effects during reperfusion, rather than during ischaemia. Endothelial ROS production and NO bioavailability are both critical for I/ R-induced alteration in BBB permeability and stroke outcome 12, 47 and ROS are known to influence claudin-5 levels in brain endothelial cells. 48 Here, we demonstrate in vitro evidence that endothelial p66
Shc silencing in H/R preserves NO bioavailability, reduces NADPH oxidase activation, and decreases ROS generation thus blunting the reduction in claudin-5 levels. This pathway may be also relevant in vivo.
To study p66 Shc gene regulation in stroke patients, we performed proof-of-principle experiments assessing its expression in PBMs of acute ischaemic stroke patients. Although it would be of particular interest and relevance to elucidate the role of cerebrovascular p66 Shc in stroke patients, sample collection in humans would prove extremely difficult thus, we selected PBMs since those are easily obtainable from whole blood and could still give us interesting insights into gene expression changes. Here we found that p66 Shc mRNA levels were increased 6 h after initial stroke symptoms and then returned to basal levels at 24 h. Moreover, p66 Shc expression at 6 h correlated to short-term neurological outcome (delta NIHSS) in stroke patients. Interestingly, delta NIHSS correlated to p66 Shc expression only in patients undergoing thrombolysis, but not in those without. Although thrombolysis is known to improve neurological outcome after stroke, 5 it is also associated with early reperfusion-induced BBB damage 49 which is known to be mediated by ROS and affects stroke outcome. 6 An increased vascular leakage also favours the accumulation of blood circulating cells in brain tissue thus causing tissue damage via production of free radicals. 11, 50 This could explain why the correlation between neurological outcome and p66 Shc expression is found only in thrombolytic patients where monocytic p66 Shc -induced ROS production and the consequent damage is likely more pronounced. In contrast, in patients not undergoing thrombolysis, the role of reperfusioninduced ROS-dependent injury is less prominent and thus neurological damage is less likely to be dependent on p66 Shc -mediated ROS. Post-ischaemic silencing of p66 Shc reduces ischaemia/reperfusion brain injury In summary, the present study sets the stage for follow-up clinical studies aimed at assessing the potential for p66
Shc to become a novel therapeutic target as an adjunct of thrombolysis for the management of acute ischaemic stroke.
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